Florida 2023 2023 Regular Session

Florida House Bill H0039 Analysis / Analysis

Filed 03/29/2023

                    This docum ent does not reflect the intent or official position of the bill sponsor or House of Representatives. 
STORAGE NAME: h0039.PEW 
DATE: 3/29/2023 
 
HOUSE OF REPRESENTATIVES STAFF ANALYSIS  
 
BILL #: CS/HB 39    Emergency Opioid Antagonists 
SPONSOR(S): Edmonds and others 
TIED BILLS:   IDEN./SIM. BILLS: SB 542 
 
REFERENCE 	ACTION ANALYST STAFF DIRECTOR or 
BUDGET/POLICY CHIEF 
1) Postsecondary Education & Workforce 
Subcommittee 
16 Y, 0 N, As CS Suppiah Kiner 
SUMMARY ANALYSIS 
The bill requires each Florida College System institution and state university to have a supply of emergency 
opioid antagonists in clearly marked locations within certain residence halls or dormitory residences. 
 
The bill also requires such emergency opioid antagonists to be easily accessible to campus law enforcement 
officers who are trained in the administration of emergency opioid antagonists. The bill provides civil and 
criminal immunity to any campus law enforcement officer trained in the administration of emergency opioid 
antagonists, who administers or attempts to administer an emergency opioid antagonist as authorized under 
laws related to emergency treatment for suspected opioid overdose and the Good Samaritan Act. The 
institution that employs the officer who acts in accordance with the provisions of the bill is also granted civil and 
criminal immunity. 
 
The bill encourages public and private partnerships to cover the costs of emergency opioid antagonists at 
Florida College System institutions and state universities.  
 
The bill requires the State Board of Education and the Board of Governors to adopt rules and regulations, 
respectively, to administer the bill’s requirements. 
 
The bill may have an indeterminate fiscal impact on state and local governments.  
 
The bill provides an effective date of July 1, 2023.    STORAGE NAME: h0039.PEW 	PAGE: 2 
DATE: 3/29/2023 
  
FULL ANALYSIS 
I.  SUBSTANTIVE ANALYSIS 
 
A. EFFECT OF PROPOSED CHANGES: 
Background 
 
Opioids are a class of drugs that can be created synthetically by laboratory scientists or derived 
naturally from the opium poppy plant.
1
 Opioids, which include, but are not limited to, fentanyl, 
oxycodone, hydrocodone, codeine, and morphine, are prescribed by doctors to relieve pain.
2
 Using 
opioids as prescribed or misusing opioids can lead to substance use disorder or addiction.
3
  
 
Opioid Overdoses and the Use of Naloxone 
 
Opioid misuse and opioid addiction can lead to overdose and death. Since 1999, over half a million 
Americans have died from opioid and opioid-involved overdoses.
4
 Naloxone is an opioid antagonist that 
is used to reverse an opioid overdose when it takes place.
5
 Naloxone, which is commonly known as 
NARCAN®, is usually administered to persons who show signs of an opioid overdose.
6
 A single 
dosage of naloxone, which can be administered via injection or nasal spray, is effective for 30 to 90 
minutes, but the effects of an opioid overdose can be felt after the naloxone wears off.
7
 Some opioids, 
like fentanyl, are more potent than others and require multiple doses of naloxone.
8
 For these reasons, 
even when emergency naloxone is administered, people experiencing an overdose need immediate 
medical attention.
9
  
 
NARCAN® Nasal Spray comes in a small, portable device for carrying or storing in a purse or pocket or 
at home and does not require specialized training to administer.
10
 Each package contains 2 ready-to-
use, single-dose nasal spray devices.
11
  
 
Opioid Misuse in Adolescents & Young Adults 
 
Data surrounding opioid misuse in adolescents and young adults is sparser and less consistent than 
data that is available for adults.
12
 But there is evidence that the prevalence of opioid misuse is 
increasing within this population.
13
 According to the 2016 National Survey on Drug Use and Health 
(NSDUH), 3.8 percent of adolescents (ages 12 to 17) and 7.8 percent of young adults (ages 18 to 25) 
engaged in opioid misuse or reported having an opioid use disorder.
14
 In 2016, opioid exposures 
accounted for over 12 percent of all deaths among 15- to 24-year-olds.
15
  
 
                                                
1
 National Opioids Crisis: Help and Resources, U.S. Department of Health & Human Services, Prevent Opioid Abuse and Addiction, 
https://www.hhs.gov/opioids/prevention/index.html (last visited January 23, 2023) 
2
 Id. 
3
 Id.  
4
 Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Opioid Data Analysis and 
Resources, https://www.cdc.gov/opioids/data/analysis-resources.html#anchor_trends_in_deaths_rates (last visited January 23, 2023) 
5
 National Institute on Drug Abuse, National Institutes of Health, Naloxone DrugFacts, 
https://nida.nih.gov/publications/drugfacts/naloxone (last visited January 23, 2023) 
6
 Id. 
7
 Id. 
8
 Id. 
9
 Id. 
10
 NARCAN® Nasal Spray, Caregiver Brochure, available at https://www.narcan.com/wp-
content/uploads/2021/12/Caregiver_Brochure.pdf  
11
 Id. 
12
 Hudgins JD, Porter JJ, Monuteaux MC, Bourgeois FT (2019) Prescription opioid use and misuse among adolescents and young 
adults in the United States: A national survey study. PLoS Med 16(11): e1002922. https://doi.org/10.1371/journal. pmed.1002922  
13
 Id. 
14
 Id. 
15
 Id.  STORAGE NAME: h0039.PEW 	PAGE: 3 
DATE: 3/29/2023 
  
On college campuses, the use of opiates has risen over the past 20 years.
16
 Between 1993 and 2005, 
the use of prescription opioids increased by 343 percent and 1 in 4 universities had an annual 
prescription opioid use prevalence of 10 percent or higher.
17
  
 
Emergency Opioid Antagonists in Florida Law 
 
Under Florida law, an “emergency opioid antagonist” refers to naloxone hydrochloride or any similarly 
acting drug that blocks the effects of opioids administered from outside the body and that is approved 
by the United States Food and Drug Administration for the treatment of an opioid overdose.
18
  
 
Pharmacists may dispense an emergency opioid antagonist pursuant to a prescription by an authorized 
health care practitioner, pharmacist’s order, or nonpatient-specific standing order.
19
 Currently, the 
following persons are authorized to possess, store, and administer emergency opioid antagonists as 
clinically indicated and are immune from any civil or criminal liability resulting from the administration of 
an emergency opioid antagonist: 
 Emergency responders (including law enforcement officers, paramedics, and emergency 
medical technicians). 
 Crime laboratory personnel (including analysts, evidence intake personnel, and crime 
laboratory supervisors). 
 Law enforcement agency or other agency personnel (including correctional probation officers 
and child protective investigators). 
 Authorized health care practitioners, dispensing health care practitioner, and pharmacists.
20
 
 
Patients (persons at risk of experiencing an opioid overdose) are authorized to store and possess 
approved emergency opioid antagonists, and in an emergency situation when a physician is not 
immediately available, administer the emergency opioid antagonist to a person believed in good faith to 
be experiencing an opioid overdose, regardless of whether that person has a prescription for an 
emergency opioid antagonist.
21
 
 
Cost of Naloxone 
 
The cost of naloxone varies widely from less than a dollar per unit for a simple ampoule or vial, to 
several thousand dollars for certain intramuscular auto-injectors.
22
 On average, naloxone costs 
approximately $30 per dose kit.
23
 The Florida Department of Children and Families, as part of its 
overdose prevention program, purchases Narcan at $75 per kit with two doses in each kit.
24
 Emergent 
Biosolutions has produced an FDA- approved naloxone nasal spray called Narcan.
25
 Emergent 
Biosolutions offers up to four free cartons of Narcan to degree-granting postsecondary institutions.
26
  
 
The Good Samaritan Act 
 
                                                
16
 Opioid Resource Center, Healio, Opioid abuse in college students requires increased efforts, 
https://www.healio.com/news/psychiatry/20171030/opioid-abuse-in-college-students-requires-increased-efforts (last visited January 
23, 2023) 
17
 Id. 
18
 Section 381.887(1)(d), F.S. 
19
 Section 381.887(3)(b), F.S. 
20
 Section 381.887(4)-(5), F.S. 
21
 Section 381.887(3)(c), F.S. 
22
 John Strang et al., Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health 
Application of an Emergency Medicine, 79(13) Drugs 1395-1418 (2019), available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728289/. 
23
 Florida Department of Education, HB 39 2023 Agency Legislative Bill Analysis (Feb. 9, 2023) (on file with the Senate Committee 
on Judiciary). 
24
 Email, Florida Department of Children and Families (Mar. 6, 2023) (on file with the Senate Committee on Judiciary). 
25
 Id. Emergent Biosolutions bought Adapt Pharma, who originally produced Narcan. 
26
 Emergent Biosolutions, Free Narcan Nasal Spray to Eligible Schools, available at https://californiamat.org/wp-
content/uploads/2022/01/Schools.PP-NAR4-US-00483-Professional-Educator-One-Pager-2021-Update.pdf.   STORAGE NAME: h0039.PEW 	PAGE: 4 
DATE: 3/29/2023 
  
The Good Samaritan Act provides immunity from civil liability for people who act in an emergency 
situation to render aid when certain factors are present. The act states, in part, that any person, 
including those licensed to practice medicine, who gratuitously and in good faith renders emergency 
care or treatment either in direct response to emergency situations at the scene of an emergency 
outside of a hospital, doctor's office, or other place having proper medical equipment, without objection 
from the injured victim or victims are immune from liability for any civil damages as a result of that care 
or treatment or as a result of any act or failure to act in providing or arranging further medical treatment 
where the person acts as an ordinary reasonably prudent person would have acted under the same or 
similar circumstances.
27
 
 
Effect of Proposed Changes 
 
The bill requires each Florida College System institution and state university to have a supply of 
emergency opioid antagonists in clearly marked locations within certain residence halls or dormitory 
residences. 
 
The bill also requires such emergency opioid antagonists to be easily accessible to campus law 
enforcement officers who are trained in the administration of emergency opioid antagonists. There are 
currently 28 FCS institutions and 12 state universities.  
 
All 12 state universities in the State University System of Florida own or operate a residence hall or 
dormitory available to students. In the 28 state colleges in the Florida College System, there are 12 
residence halls or dormitories available to students. However, only three of these residence halls or 
dormitories are owned or operated by a state college. They are located at Chipola College, College of 
the Florida Keys, and Florida Gateway College. 
 
The bill provides civil and criminal immunity to any campus law enforcement officer trained in the 
administration of emergency opioid antagonists, who administers or attempts to administer an 
emergency opioid antagonist as authorized under laws related to emergency treatment for suspected 
opioid overdose and the Good Samaritan Act. The institution that employs the officer who acts in 
accordance with the provisions of the bill is also granted civil and criminal immunity. 
 
The bill encourages public and private partnerships to cover the costs of emergency opioid antagonists 
at Florida College System institutions.  
 
The bill requires the State Board of Education and the Board of Governors to adopt rules and 
regulations, respectively, to administer the bill’s requirements. 
 
The bill provides an effective date of July 1, 2023. 
 
B. SECTION DIRECTORY: 
Section 1: Creating s. 1004.0971, F.S., requiring Florida College System institutions and state 
universities to have a supply of emergency opioid antagonists in clearly marked locations within certain 
residence halls or dormitory residences. 
  
Section 2: Provides an effective date of July 1, 2023. 
II.  FISCAL ANALYSIS & ECONOMIC IMPACT STATEMENT 
 
A. FISCAL IMPACT ON STATE GOVERNMENT: 
 
1. Revenues: 
None. 
 
                                                
27
 Section 768.13(2)(a), F.S.  STORAGE NAME: h0039.PEW 	PAGE: 5 
DATE: 3/29/2023 
  
2. Expenditures: 
See Fiscal Comments.  
 
B. FISCAL IMPACT ON LOCAL GOVERNMENTS: 
 
1. Revenues: 
None. 
 
2. Expenditures: 
See Fiscal Comments.  
 
C. DIRECT ECONOMIC IMPACT ON PRIVATE SECTOR: 
None.  
 
D. FISCAL COMMENTS: 
FCS institutions and state universities may incur expenses for the purchase and storage of emergency 
opioid antagonists in residence halls and dormitory residences, unless such emergency opioid 
antagonists are provided free of charge or some other entity covers the cost. The cost of naloxone 
varies widely from less than a dollar per unit for a simple ampoule or vial, to several thousand dollars 
for certain intramuscular auto-injectors.
28
 On average, naloxone costs approximately $30 per dose kit.
29
 
The Florida Department of Children and Families, as part of its overdose prevention program, 
purchases Narcan at $75 per kit with two doses in each kit.
30
 Emergent Biosolutions has produced an 
FDA- approved naloxone nasal spray called Narcan.
31
 Emergent Biosolutions offers up to four free 
cartons of Narcan to degree-granting postsecondary institutions.
32
  
 
Opioid antagonists like naloxone have a shelf life of approximately 18 to 24 months from the date of 
manufacture and need to be replaced accordingly.
33
  
III.  COMMENTS 
 
A. CONSTITUTIONAL ISSUES: 
 
 1. Applicability of Municipality/County Mandates Provision: 
None. 
 
 2. Other: 
None. 
 
B. RULE-MAKING AUTHORITY: 
The bill requires the State Board of Education and the Board of Governors to adopt rules and 
regulations, respectively, to administer the bill’s requirements. 
 
                                                
28
 John Strang et al., Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health 
Application of an Emergency Medicine, 79(13) Drugs 1395-1418 (2019), available at 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728289/. 
29
 Florida Department of Education, HB 39 2023 Agency Legislative Bill Analysis (Feb. 9, 2023) (on file with the Senate Committee 
on Judiciary). 
30
 Email, Florida Department of Children and Families (Mar. 6, 2023) (on file with the Senate Committee on Judiciary). 
31
 Id. Emergent Biosolutions bought Adapt Pharma, who originally produced Narcan. 
32
 Emergent Biosolutions, Free Narcan Nasal Spray to Eligible Schools, available at https://californiamat.org/wp-
content/uploads/2022/01/Schools.PP-NAR4-US-00483-Professional-Educator-One-Pager-2021-Update.pdf.  
33
 Addictions, Drug & Alcohol Institute, University of Washington, Research Suggests Naloxone May Be Good Past Its Expiration 
Date, https://adai.uw.edu/research-suggests-naloxone-may-be-good-past-its-expiration-
date/#:~:text=Naloxone%20products%20typically%20have%20an,and%20safety%20of%20a%20drug. (last visited January 23, 2023)  STORAGE NAME: h0039.PEW 	PAGE: 6 
DATE: 3/29/2023 
  
C. DRAFTING ISSUES OR OTHER COMMENTS: 
None. 
IV.  AMENDMENTS/COMMITTEE SUBSTITUTE CHANGES 
On March 29, 2023, the Postsecondary Education & Workforce Subcommittee adopted a Proposed 
Committee Substitute (PCS) and reported the PCS favorably as a committee substitute. The PCS differs 
from HB 39 in the following way: 
 requires state universities and state colleges to make the emergency opioid antagonists in the 
residence halls or dormitories easily accessible to campus law enforcement instead of resident 
assistants. 
 removes the requirement that state colleges and state universities provide training to resident 
assistants in the administration of emergency opioid antagonists, as well as the provision 
providing trained resident assistants criminal and civil liability immunity. These revisions are 
consistent with the provision requiring the emergency opioid antagonists to be easily accessible 
to law enforcement instead of resident assistants.